Better Context → Better Decisions
Context counts in life sciences. The FENIX analyst team is tirelessly using its experience to put you in a position to succeed. Below, our readers without corporate access will find a wealth of contextualized life science insight ready to be purchased in the FENIX Marketplace. If our content sharing limitations are inconvenient for you, reach out to Brady for unlimited corporate, institutional, or individual access.
$599
Posted in: Allogeneic, Autologous, BCMA, CAR-T Apr 20 | 2020Janssen and Fate Collaborate to Develop iPSC-derived CAR-T and NK TherapiesPurchase Blast$599
Posted in: Basal Insulin, Glucose Monitoring, Insulin Delivery, Other Apr 16 | 2020Abbott Q1 '20 Earnings Update; Provention Bio Initiates Rolling BLA for Teplizumab; Lilly Launches Additional Humalog AGs; Insulet’s COVID-19 ResponsePurchase Blast$599
Posted in: Allogeneic, Autologous, BCMA, CAR-T Apr 16 | 2020J&J Q1 2020 Earnings UpdatePurchase Blast$599
Posted in: Insulin Delivery Apr 15 | 2020Afrezza Promotional Update; MannKind Receives $4.9M Forgivable LoanPurchase Blast$599
Posted in: Basal Insulin, Bolus Insulin Apr 14 | 2020Novo Offers Free Insulin in COVID-19 ResponsePurchase Blast$599
Posted in: Insulin Delivery Apr 13 | 2020Thoughts on i2O, the Harvard Oral Peptide Delivery SpinoutPurchase Blast$599
Posted in: Glucose Monitoring, Other Apr 09 | 2020Livongo Partners with Prognos HealthPurchase Blast$599
Posted in: Glucose Monitoring, Insulin Delivery Apr 08 | 2020Abbott's Libre in Hospitalized Patients; Companion Medical Launches Fixed Dose and Meal EstimationPurchase Blast$599
Posted in: GLP-1RA Apr 08 | 2020Trulicity CV Protection DTC Initiated; Lilly Announces $35 Co-Pay for COVID-19 HelpPurchase Blast$599
Posted in: Allogeneic, Autologous, CAR-T, CD123, CD19, CD22, CS1 Apr 08 | 2020Cellectis Q4 '19 Earnings UpdatePurchase Blast$599
Posted in: Allogeneic, Autologous, BCMA, CAR-T, CS1 Apr 08 | 2020Kite Acquires Rights to Certain Teneobio Antibodies for Multiple Myeloma CAR-T Therapies (including BCMA)Purchase Blast$599
Posted in: Glucose Monitoring Apr 03 | 2020CGM: Thoughts on Lifescan/Sanvita CGM Trial Impact from COVID-19Purchase Blast$599
Posted in: Basal Insulin Apr 01 | 2020Biocon's Malaysian Facility Passes Pre-Approval Glargine FDA InspectionPurchase Blast$599
Posted in: Glucagon Mar 31 | 2020Glucagon: Zealand Submits NDA for Dasiglucagon HypoPal Rescue PenPurchase Blast$599
Posted in: GLP-1RA Mar 27 | 2020FENIX Analysis: Ozempic and Trulicity CV Indication Initial PromotionPurchase Blast$599
Posted in: Glucose Monitoring Mar 26 | 2020Senseonics Suspends US Commercial Sales to New PatientsPurchase Blast$599
Posted in: Other Mar 25 | 2020AZ Partners with Silence Therapeutics for siRNA Targeting; AZ Leverages BrightInsight for Digital PlatformPurchase BlastGet the Latest Analysis
Stay informed and aligned with frequent updates to keep a pulse on the industry.
If you already have an account, please log in. If you have any questions or would like to subscribe to our services, please contact Brady.